CSE Interview with Rob Abenante CEO of Abattis Bioceuticals Corp.

0

Share

Other News

Abattis Announces Successful Closing of Pi Nutrients May 31, 2019
Abattis Announces Successful Closing of Pro Natura Acquisition May 21, 2019
Abattis Announces Acquisition of European Nutraceutical Company and Provides Corporate Updates April 3, 2019
Abattis Provides Update on Trading Halt and Announces Management Conference Call February 19, 2019
COMFORT on Desert Living NBC February 7, 2019

Abattis Bioceuticals is a life sciences and biotechnology company that aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry in Canada.

Exchange Listings
CSE: ATT | OTC: ATTBF

Subscribe To Our News List
Sign up to receive alerts on Abattis news releases and product announcements

Email:

Abattis Bioceuticals Corporation
#1200 - 625 Howe Street
Vancouver, BC | V6C 2T6
T: 1-808-650-3007

Follow @abattis

Disclaimer
Privacy Policy
Terms and Conditions
Return Policy